PMC:7441788 / 16449-16953 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T101","span":{"begin":363,"end":371},"obj":"Disease"}],"attributes":[{"id":"A101","pred":"mondo_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Borba et al [49]. Randomized controlled trial High-dose CQ group: n = 40;Low-dose CQ group:n = 41 high-dose CQ (600 mg/2 times/day, for 10 day);low-dose CQ (450 mg/2 times/day for 5 days, double dose on 1st day) The mortality rate in the high-dose group was more than double that in low-dose group Double-blind study; 2 dosages of CQ for the first time in severe COVID-19 Small sample size; single-center design; Lack of a placebo control; Lack of exclusion criteria based on the QTc interval at baseline"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T177","span":{"begin":95,"end":97},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"},{"id":"T178","span":{"begin":421,"end":422},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Borba et al [49]. Randomized controlled trial High-dose CQ group: n = 40;Low-dose CQ group:n = 41 high-dose CQ (600 mg/2 times/day, for 10 day);low-dose CQ (450 mg/2 times/day for 5 days, double dose on 1st day) The mortality rate in the high-dose group was more than double that in low-dose group Double-blind study; 2 dosages of CQ for the first time in severe COVID-19 Small sample size; single-center design; Lack of a placebo control; Lack of exclusion criteria based on the QTc interval at baseline"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T210","span":{"begin":56,"end":58},"obj":"Chemical"},{"id":"T211","span":{"begin":59,"end":64},"obj":"Chemical"},{"id":"T212","span":{"begin":82,"end":84},"obj":"Chemical"},{"id":"T213","span":{"begin":108,"end":110},"obj":"Chemical"},{"id":"T214","span":{"begin":153,"end":155},"obj":"Chemical"},{"id":"T215","span":{"begin":248,"end":253},"obj":"Chemical"},{"id":"T216","span":{"begin":292,"end":297},"obj":"Chemical"},{"id":"T217","span":{"begin":331,"end":333},"obj":"Chemical"}],"attributes":[{"id":"A210","pred":"chebi_id","subj":"T210","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A211","pred":"chebi_id","subj":"T211","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A212","pred":"chebi_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A213","pred":"chebi_id","subj":"T213","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A214","pred":"chebi_id","subj":"T214","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A215","pred":"chebi_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A216","pred":"chebi_id","subj":"T216","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A217","pred":"chebi_id","subj":"T217","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"}],"text":"Borba et al [49]. Randomized controlled trial High-dose CQ group: n = 40;Low-dose CQ group:n = 41 high-dose CQ (600 mg/2 times/day, for 10 day);low-dose CQ (450 mg/2 times/day for 5 days, double dose on 1st day) The mortality rate in the high-dose group was more than double that in low-dose group Double-blind study; 2 dosages of CQ for the first time in severe COVID-19 Small sample size; single-center design; Lack of a placebo control; Lack of exclusion criteria based on the QTc interval at baseline"}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T131","span":{"begin":56,"end":58},"obj":"Chemical"},{"id":"T132","span":{"begin":82,"end":84},"obj":"Chemical"},{"id":"T133","span":{"begin":108,"end":110},"obj":"Chemical"},{"id":"T134","span":{"begin":153,"end":155},"obj":"Chemical"},{"id":"T135","span":{"begin":331,"end":333},"obj":"Chemical"}],"attributes":[{"id":"A135","pred":"chebi_id","subj":"T135","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A134","pred":"chebi_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A131","pred":"chebi_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A133","pred":"chebi_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A132","pred":"chebi_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"}],"text":"Borba et al [49]. Randomized controlled trial High-dose CQ group: n = 40;Low-dose CQ group:n = 41 high-dose CQ (600 mg/2 times/day, for 10 day);low-dose CQ (450 mg/2 times/day for 5 days, double dose on 1st day) The mortality rate in the high-dose group was more than double that in low-dose group Double-blind study; 2 dosages of CQ for the first time in severe COVID-19 Small sample size; single-center design; Lack of a placebo control; Lack of exclusion criteria based on the QTc interval at baseline"}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T103","span":{"begin":363,"end":371},"obj":"Species"}],"attributes":[{"id":"A103","pred":"ncbi_taxonomy_id","subj":"T103","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"Borba et al [49]. Randomized controlled trial High-dose CQ group: n = 40;Low-dose CQ group:n = 41 high-dose CQ (600 mg/2 times/day, for 10 day);low-dose CQ (450 mg/2 times/day for 5 days, double dose on 1st day) The mortality rate in the high-dose group was more than double that in low-dose group Double-blind study; 2 dosages of CQ for the first time in severe COVID-19 Small sample size; single-center design; Lack of a placebo control; Lack of exclusion criteria based on the QTc interval at baseline"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T123","span":{"begin":0,"end":17},"obj":"Sentence"},{"id":"T124","span":{"begin":18,"end":504},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Borba et al [49]. Randomized controlled trial High-dose CQ group: n = 40;Low-dose CQ group:n = 41 high-dose CQ (600 mg/2 times/day, for 10 day);low-dose CQ (450 mg/2 times/day for 5 days, double dose on 1st day) The mortality rate in the high-dose group was more than double that in low-dose group Double-blind study; 2 dosages of CQ for the first time in severe COVID-19 Small sample size; single-center design; Lack of a placebo control; Lack of exclusion criteria based on the QTc interval at baseline"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"659","span":{"begin":56,"end":58},"obj":"Chemical"},{"id":"660","span":{"begin":82,"end":84},"obj":"Chemical"},{"id":"661","span":{"begin":108,"end":110},"obj":"Chemical"},{"id":"662","span":{"begin":153,"end":155},"obj":"Chemical"},{"id":"663","span":{"begin":331,"end":333},"obj":"Chemical"},{"id":"706","span":{"begin":216,"end":225},"obj":"Disease"},{"id":"707","span":{"begin":363,"end":371},"obj":"Disease"}],"attributes":[{"id":"A660","pred":"pubann:denotes","subj":"660","obj":"MESH:D002738"},{"id":"A706","pred":"pubann:denotes","subj":"706","obj":"MESH:D003643"},{"id":"A662","pred":"pubann:denotes","subj":"662","obj":"MESH:D002738"},{"id":"A707","pred":"pubann:denotes","subj":"707","obj":"MESH:C000657245"},{"id":"A661","pred":"pubann:denotes","subj":"661","obj":"MESH:D002738"},{"id":"A663","pred":"pubann:denotes","subj":"663","obj":"MESH:D002738"},{"id":"A659","pred":"pubann:denotes","subj":"659","obj":"MESH:D002738"}],"text":"Borba et al [49]. Randomized controlled trial High-dose CQ group: n = 40;Low-dose CQ group:n = 41 high-dose CQ (600 mg/2 times/day, for 10 day);low-dose CQ (450 mg/2 times/day for 5 days, double dose on 1st day) The mortality rate in the high-dose group was more than double that in low-dose group Double-blind study; 2 dosages of CQ for the first time in severe COVID-19 Small sample size; single-center design; Lack of a placebo control; Lack of exclusion criteria based on the QTc interval at baseline"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T94","span":{"begin":363,"end":371},"obj":"Disease"}],"attributes":[{"id":"A94","pred":"mondo_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Borba et al [49]. Randomized controlled trial High-dose CQ group: n = 40;Low-dose CQ group:n = 41 high-dose CQ (600 mg/2 times/day, for 10 day);low-dose CQ (450 mg/2 times/day for 5 days, double dose on 1st day) The mortality rate in the high-dose group was more than double that in low-dose group Double-blind study; 2 dosages of CQ for the first time in severe COVID-19 Small sample size; single-center design; Lack of a placebo control; Lack of exclusion criteria based on the QTc interval at baseline"}

{"project":"LitCovid-PubTator","denotations":[{"id":"659","span":{"begin":56,"end":58},"obj":"Chemical"},{"id":"660","span":{"begin":82,"end":84},"obj":"Chemical"},{"id":"661","span":{"begin":108,"end":110},"obj":"Chemical"},{"id":"662","span":{"begin":153,"end":155},"obj":"Chemical"},{"id":"663","span":{"begin":331,"end":333},"obj":"Chemical"},{"id":"706","span":{"begin":216,"end":225},"obj":"Disease"},{"id":"707","span":{"begin":363,"end":371},"obj":"Disease"}],"attributes":[{"id":"A659","pred":"tao:has_database_id","subj":"659","obj":"MESH:D002738"},{"id":"A660","pred":"tao:has_database_id","subj":"660","obj":"MESH:D002738"},{"id":"A661","pred":"tao:has_database_id","subj":"661","obj":"MESH:D002738"},{"id":"A662","pred":"tao:has_database_id","subj":"662","obj":"MESH:D002738"},{"id":"A663","pred":"tao:has_database_id","subj":"663","obj":"MESH:D002738"},{"id":"A706","pred":"tao:has_database_id","subj":"706","obj":"MESH:D003643"},{"id":"A707","pred":"tao:has_database_id","subj":"707","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Borba et al [49]. Randomized controlled trial High-dose CQ group: n = 40;Low-dose CQ group:n = 41 high-dose CQ (600 mg/2 times/day, for 10 day);low-dose CQ (450 mg/2 times/day for 5 days, double dose on 1st day) The mortality rate in the high-dose group was more than double that in low-dose group Double-blind study; 2 dosages of CQ for the first time in severe COVID-19 Small sample size; single-center design; Lack of a placebo control; Lack of exclusion criteria based on the QTc interval at baseline"}

{"project":"LitCovid-sentences","denotations":[{"id":"T123","span":{"begin":0,"end":17},"obj":"Sentence"},{"id":"T124","span":{"begin":18,"end":504},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Borba et al [49]. Randomized controlled trial High-dose CQ group: n = 40;Low-dose CQ group:n = 41 high-dose CQ (600 mg/2 times/day, for 10 day);low-dose CQ (450 mg/2 times/day for 5 days, double dose on 1st day) The mortality rate in the high-dose group was more than double that in low-dose group Double-blind study; 2 dosages of CQ for the first time in severe COVID-19 Small sample size; single-center design; Lack of a placebo control; Lack of exclusion criteria based on the QTc interval at baseline"}